Lung Cancer Research - Symptoms, Smoking, Genetics, Treatment, Causes

Lung Cancer Research Today is a free monthly online journal that collates and summarizes the latest research about Lung Cancer, including details on symptoms, smoking, genetics, treatment, causes.


Lung Cancer Research Today

Home

View Latest Issue

Information About Lung Cancer

Books on Lung Cancer

Mesothelioma Lung Cancer

Advertising in Research Today

View Other Research Today Publications

Volume 2 (2005), Issue 5 (May)

  1. Surgical treatment for metastatic malignancies. Pulmonary metastasis: indications and outcomes.
    Int J Clin Oncol, 10(2): 81-5. [Abstract] [Full-text]
  2. Surgical treatment of superior sulcus tumors.
    Surg Today, 35(5): 357-63. [Abstract] [Full-text]
  3. Familial cystic nephroma in two siblings with pleuropulmonary blastoma.
    Pathol Oncol Res, 11(1): 53-6. [Abstract] [Full-text]
  4. High frequency of frameshift mutation on p53 gene in Taiwanese with non small cell lung cancer.
    Cancer Lett, 222(2): 195-204. [Abstract] [Full-text]
  5. Anti-proliferative activity of Bupleurum scrozonerifolium in A549 human lung cancer cells in vitro and in vivo.
    Cancer Lett, 222(2): 183-93. [Abstract] [Full-text]
  6. Modulation of response to radiation of human lung cancer cells following insulin-like growth factor 1 receptor inactivation.
    Cancer Lett, 222(2): 173-81. [Abstract] [Full-text]
  7. Immunization with adenoviral vectors carrying recombinant IL-12 and E7 enhanced the antitumor immunity to human papillomavirus 16-associated tumor.
    Gynecol Oncol, 97(2): 559-67. [Abstract] [Full-text]
  8. Estrogen and growth factor receptor interactions in human breast and non-small cell lung cancer cells.
    Steroids, 70(5): 372-81. [Abstract] [Full-text]
  9. Malignant transformation of wild-type but not plasminogen activator inhibitor-1 gene-deficient fibroblasts decreases cellular sensitivity to chemotherapy-mediated apoptosis.
    Eur J Cancer, 41(7): 1095-100. [Abstract] [Full-text]
  10. MRI findings of primary small-cell carcinoma of kidney.
    Magn Reson Imaging, 23(3): 515-7. [Abstract] [Full-text]
  11. The role of bisphosphonates in the management of advanced cancer with a focus on non-small-cell lung cancer. Part 2: Clinical studies and economic analyses.
    Oncology, 68(1): 18-22. [Abstract] [Full-text]
  12. The role of bisphosphonates in the management of advanced cancer with a focus on non-small-cell lung cancer. Part 1: Mechanisms of action, role of biomarkers and preclinical applications.
    Oncology, 68(1): 10-7. [Abstract] [Full-text]
  13. Expression of ADAM15 in lung carcinomas.
    Virchows Arch, 446(4): 421-9. [Abstract] [Full-text]
  14. Antitumor effect of beta-elemene in non-small-cell lung cancer cells is mediated via induction of cell cycle arrest and apoptotic cell death.
    Cell Mol Life Sci, 62(7): 881-93. [Abstract] [Full-text]
  15. Randomized phase II evaluation of aprinocarsen in combination with gemcitabine and cisplatin for patients with advanced/metastatic non-small cell lung cancer.
    Invest New Drugs, 23(3): 263-9. [Abstract] [Full-text]
  16. Limited resection trial for pulmonary ground-glass opacity nodules: fifty-case experience.
    J Thorac Cardiovasc Surg, 129(5): 991-6. [Abstract] [Full-text]
  17. Phase II trial of postoperative adjuvant cisplatin and etoposide in patients with completely resected stage I-IIIa small cell lung cancer: the Japan Clinical Oncology Lung Cancer Study Group Trial (JCOG9101).
    J Thorac Cardiovasc Surg, 129(5): 977-83. [Abstract] [Full-text]
  18. RASSF1A suppresses the c-Jun-NH2-kinase pathway and inhibits cell cycle progression.
    Cancer Res, 65(9): 3682-90. [Abstract] [Full-text]
  19. Dominant-negative Notch3 receptor inhibits mitogen-activated protein kinase pathway and the growth of human lung cancers.
    Cancer Res, 65(9): 3555-61. [Abstract] [Full-text]
  20. Phase I trial of the matrix metalloproteinase inhibitor marimastat combined with carboplatin and paclitaxel in patients with advanced non-small cell lung cancer.
    Clin Cancer Res, 11(9): 3417-24. [Abstract] [Full-text]
  21. A phase I clinical trial of thoracic radiotherapy and concurrent celecoxib for patients with unfavorable performance status inoperable/unresectable non-small cell lung cancer.
    Clin Cancer Res, 11(9): 3342-8. [Abstract] [Full-text]
  22. Int6 expression can predict survival in early-stage non-small cell lung cancer patients.
    Clin Cancer Res, 11(9): 3198-204. [Abstract] [Full-text]
  23. Basiliximab in lung transplantation: preliminary experience.
    Transplant Proc, 37(3): 1534-6. [Abstract] [Full-text]
  24. Selective activation of PPARgamma in breast, colon, and lung cancer cell lines.
    Mol Cell Endocrinol, 235(1): 21-9. [Abstract] [Full-text]
  25. Multi-detector row CT: is prospective electrocardiographic triggering improving the detection of small pulmonary tumors?
    Acad Radiol, 12(5): 614-9. [Abstract] [Full-text]
  26. Computer-aided diagnosis of the solitary pulmonary nodule.
    Acad Radiol, 12(5): 570-5. [Abstract] [Full-text]
  27. The role of p53 in treatment responses of lung cancer.
    Biochem Biophys Res Commun, 331(3): 868-80. [Abstract] [Full-text]
  28. Reduction of PTEN protein and loss of epidermal growth factor receptor gene mutation in lung cancer with natural resistance to gefitinib (IRESSA).
    Br J Cancer, 92(9): 1711-9. [Abstract] [Full-text]
  29. Randomized phase III trial of dose-dense chemotherapy supported by whole-blood hematopoietic progenitors in better-prognosis small-cell lung cancer.
    J Natl Cancer Inst, 97(9): 666-74. [Abstract] [Full-text]
  30. Epidermal growth factor receptor gene and protein and gefitinib sensitivity in non-small-cell lung cancer.
    J Natl Cancer Inst, 97(9): 643-55. [Abstract] [Full-text]
  31. Paratesticular desmoplastic small round cell tumor: case report.
    Urol Oncol, 23(2): 132-4. [Abstract] [Full-text]
  32. Differences in biodistribution between 99mTc-depreotide, 111In-DTPA-octreotide, and 177Lu-DOTA-Tyr3-octreotate in a small cell lung cancer animal model.
    Cancer Biother Radiopharm, 20(2): 231-6. [Abstract] [Full-text]
  33. Correlation between development of pulmonary edema and response of pulmonary metastases of metastatic melanoma and kidney cancer to high-dose continuous-infusion interleukin-2.
    Cancer Biother Radiopharm, 20(2): 151-4. [Abstract] [Full-text]
  34. Usefulness of thyroid transcription factor-1 immunohistochemical staining in the differential diagnosis of primary pulmonary tumors of dogs.
    Vet Pathol, 42(3): 315-20. [Abstract] [Full-text]
  35. Results of a phase I dose-escalation study using three-dimensional conformal radiotherapy in the treatment of inoperable nonsmall cell lung carcinoma.
    Cancer, 103(10): 2118-27. [Abstract] [Full-text]
  36. Relation between smoking cessation and receiving results from three annual spiral chest computed tomography scans for lung carcinoma screening.
    Cancer, 103(10): 2154-62. [Abstract] [Full-text]
  37. Imatinib mesylate lacks activity in small cell lung carcinoma expressing c-kit protein: a phase II clinical trial.
    Cancer, 103(10): 2128-31. [Abstract] [Full-text]
  38. Compensation for respiratory motion by gated radiotherapy: an experimental study.
    Phys Med Biol, 50(10): 2405-14. [Abstract] [Full-text]
  39. Residential radon in Canada: an uncertainty analysis of population and individual lung cancer risk.
    Risk Anal, 25(2): 253-69. [Abstract] [Full-text]
  40. Ethnic disparities in the treatment of stage I non-small cell lung cancer.
    Am J Respir Crit Care Med, 171(10): 1158-63. [Abstract] [Full-text]
  41. Combination treatment of vertebral metastases using image-guided percutaneous radiofrequency ablation and vertebroplasty: a case report.
    Surg Neurol, 63(5): 469-74; discussion 474-5. [Abstract] [Full-text]
  42. Curcumin enhances Vinorelbine mediated apoptosis in NSCLC cells by the mitochondrial pathway.
    Biochem Biophys Res Commun, 331(4): 1245-52. [Abstract] [Full-text]
  43. Roles for USF-2 in lung cancer proliferation and bronchial carcinogenesis.
    J Pathol, 206(2): 151-9. [Abstract] [Full-text]
  44. PEGylated adenovirus vectors containing RGD peptides on the tip of PEG show high transduction efficiency and antibody evasion ability.
    J Gene Med, 7(5): 604-12. [Abstract] [Full-text]
  45. Tumor-dendritic cell fusion as a basis for cancer immunotherapy.
    Otolaryngol Head Neck Surg, 132(5): 755-64. [Abstract] [Full-text]
  46. Endoscopic ultrasound for thoracic malignancy: a review.
    Curr Probl Diagn Radiol, 34(3): 106-15. [Abstract] [Full-text]
  47. Systemic therapy of advanced bronchioloalveolar cell carcinoma: challenges and opportunities.
    J Clin Oncol, 23(14): 3288-93. [Abstract] [Full-text]
  48. Evolving concepts in the pathology and computed tomography imaging of lung adenocarcinoma and bronchioloalveolar carcinoma.
    J Clin Oncol, 23(14): 3279-87. [Abstract] [Full-text]
  49. Adjuvant chemotherapy in completely resected non-small-cell lung cancer.
    J Clin Oncol, 23(14): 3270-8. [Abstract] [Full-text]
  50. Multimodality therapy for stage III non-small-cell lung cancer.
    J Clin Oncol, 23(14): 3257-69. [Abstract] [Full-text]
  51. Angiogenesis and lung cancer: prognostic and therapeutic implications.
    J Clin Oncol, 23(14): 3243-56. [Abstract] [Full-text]
  52. Epidermal growth factor receptor inhibitors in the treatment of non-small-cell lung cancer.
    J Clin Oncol, 23(14): 3235-42. [Abstract] [Full-text]
  53. Epidermal growth factor receptor mutations in non-small-cell lung cancer: implications for treatment and tumor biology.
    J Clin Oncol, 23(14): 3227-34. [Abstract] [Full-text]
  54. Genomic and proteomic profiling of lung cancers: lung cancer classification in the age of targeted therapy.
    J Clin Oncol, 23(14): 3219-26. [Abstract] [Full-text]
  55. Lung cancer in women.
    J Clin Oncol, 23(14): 3212-8. [Abstract] [Full-text]
  56. Functional imaging in lung cancer.
    J Clin Oncol, 23(14): 3203-11. [Abstract] [Full-text]
  57. New developments in lung cancer screening.
    J Clin Oncol, 23(14): 3198-202. [Abstract] [Full-text]
  58. Advances in the biology of lung cancer chemoprevention.
    J Clin Oncol, 23(14): 3186-97. [Abstract] [Full-text]
  59. Epidemiology of lung cancer: looking to the future.
    J Clin Oncol, 23(14): 3175-85. [Abstract] [Full-text]
  60. Dose heterogeneity in the target volume and intensity-modulated radiotherapy to escalate the dose in the treatment of non-small-cell lung cancer.
    Int J Radiat Oncol Biol Phys, 62(2): 561-70. [Abstract] [Full-text]
  61. Benefit of respiration-gated stereotactic radiotherapy for stage I lung cancer: an analysis of 4DCT datasets.
    Int J Radiat Oncol Biol Phys, 62(2): 554-60. [Abstract] [Full-text]
  62. Phase I study of thoracic radiation dose escalation with concurrent chemotherapy for patients with limited small-cell lung cancer: Report of Radiation Therapy Oncology Group (RTOG) protocol 97-12.
    Int J Radiat Oncol Biol Phys, 62(2): 342-50. [Abstract] [Full-text]
  63. NAT2 fast acetylator genotype is associated with an increased risk of lung cancer among never-smoking women in Taiwan.
    Cancer Lett, 223(1): 93-101. [Abstract] [Full-text]
  64. Clinical benefit in NSCLC: advanced-stage patients require symptom-improving palliation. Experiences from the 'Iressa' expanded access program.
    Onkologie, 28(4): 195-8. [Abstract] [Full-text]
  65. PRIMA-1(MET) synergizes with cisplatin to induce tumor cell apoptosis.
    Oncogene, 24(21): 3484-91. [Abstract] [Full-text]
  66. RNA silencing of S-phase kinase-interacting protein 2 inhibits proliferation and centrosome amplification in lung cancer cells.
    Oncogene, 24(21): 3409-18. [Abstract] [Full-text]
  67. Repeat pulmonary resection for isolated recurrent lung metastases yields results comparable to those after first pulmonary resection in colorectal cancer.
    World J Surg, 29(3): 363-8. [Abstract] [Full-text]
  68. Randomized phase II study comparing topotecan/cisplatin administration for 5 days versus 3 days in the treatment of extensive stage small cell lung cancer (SCLC).
    Lung Cancer, 48(3): 415-22. [Abstract] [Full-text]
  69. Topotecan and etoposide as first-line therapy for extensive disease small cell lung cancer: a phase II trial of a platinum-free regimen.
    Lung Cancer, 48(3): 409-13. [Abstract] [Full-text]
  70. Phase II trial of karenitecin in patients with relapsed or refractory non-small cell lung cancer (CALGB 30004).
    Lung Cancer, 48(3): 399-407. [Abstract] [Full-text]
  71. Post-operative radiotherapy (PORT) or chemoradiotherapy (CPORT) following resection of stages II and IIIA non-small cell lung cancer (NSCLC) does not increase the expected risk of death from intercurrent disease (DID) in Eastern Cooperative Oncology Group (ECOG) trial E3590.
    Lung Cancer, 48(3): 389-97. [Abstract] [Full-text]
  72. Cost-minimisation analysis comparing gemcitabine/cisplatin, paclitaxel/carboplatin and vinorelbine/cisplatin in the treatment of advanced non-small cell lung cancer in Italy.
    Lung Cancer, 48(3): 379-87. [Abstract] [Full-text]
  73. Health-related quality of life in patients undergoing drug therapy for advanced non-small-cell lung cancer.
    Lung Cancer, 48(3): 365-77. [Abstract] [Full-text]
  74. EUS-guided FNA of centrally located lung tumours following a non-diagnostic bronchoscopy.
    Lung Cancer, 48(3): 357-61; discussion 363-4. [Abstract] [Full-text]
  75. Prognostic impact of liberated domain I of the urokinase plasminogen activator receptor in squamous cell lung cancer tissue.
    Lung Cancer, 48(3): 349-55. [Abstract] [Full-text]
  76. Prognostication of small-sized primary pulmonary adenocarcinomas by histopathological and karyometric analysis.
    Lung Cancer, 48(3): 339-48. [Abstract] [Full-text]
  77. Cytological characteristics of pulmonary large cell neuroendocrine carcinoma.
    Lung Cancer, 48(3): 331-7. [Abstract] [Full-text]
  78. Frequent loss of E-cadherin and/or catenins in intrabronchial lesions during carcinogenesis of the bronchial epithelium.
    Lung Cancer, 48(3): 323-30. [Abstract] [Full-text]
  79. Polymorphisms in the promoter region of neutrophil elastase gene and lung cancer risk.
    Lung Cancer, 48(3): 315-21. [Abstract] [Full-text]
  80. Effective detection of bronchial preinvasive lesions by a new autofluorescence imaging bronchovideoscope system.
    Lung Cancer, 48(3): 307-13. [Abstract] [Full-text]
  81. Expression of the p16(INK4a) gene product, methylation of the p16(INK4a) promoter region and expression of the polycomb-group gene BMI-1 in squamous cell lung carcinoma and premalignant endobronchial lesions.
    Lung Cancer, 48(3): 299-306. [Abstract] [Full-text]
  82. Cisplatin and gemcitabine induction chemotherapy followed by concurrent chemoradiotherapy or surgery for locally advanced non-small cell lung cancer.
    Intern Med J, 35(6): 336-42. [Abstract] [Full-text]
  83. Carbamoylphosphonate matrix metalloproteinase inhibitors 3: in vivo evaluation of cyclopentylcarbamoylphosphonic acid in experimental metastasis and angiogenesis.
    Clin Cancer Res, 11(10): 3925-9. [Abstract] [Full-text]
  84. Mutation in the tyrosine kinase domain of epidermal growth factor receptor is a predictive and prognostic factor for gefitinib treatment in patients with non-small cell lung cancer.
    Clin Cancer Res, 11(10): 3750-7. [Abstract] [Full-text]
  85. Prognostic significance of microvascularization in cases of operated lung cancer.
    Eur J Cardiothorac Surg, 27(6): 1106-11. [Abstract] [Full-text]
  86. Early and long-term results of lung resection for non-small-cell lung cancer in patients with severe ventilatory impairment.
    Eur J Cardiothorac Surg, 27(6): 1099-105. [Abstract] [Full-text]
  87. Comparison of neoadjuvant cisplatin-based chemotherapy versus radiochemotherapy followed by resection for stage III (N2) NSCLC.
    Eur J Cardiothorac Surg, 27(6): 1092-8. [Abstract] [Full-text]
  88. Postoperative adjuvant chemotherapy for stage I non-small cell lung cancer.
    Eur J Cardiothorac Surg, 27(6): 1086-91. [Abstract] [Full-text]
  89. Anterograde versus retrograde isolated lung perfusion with melphalan in the WAG-Rij rat.
    Eur J Cardiothorac Surg, 27(6): 1083-5. [Abstract] [Full-text]
  90. Video-assisted transcatheter lung perfusion regional chemotherapy.
    Eur J Cardiothorac Surg, 27(6): 1079-82. [Abstract] [Full-text]
  91. Rapid detection of single nucleotide polymorphisms related with lung cancer susceptibility of Chinese population.
    Cancer Lett, 223(2): 265-74. [Abstract] [Full-text]
  92. Etoposide (VP-16) elicits apoptosis following prolonged G2-M cell arrest in p53-mutated human non-small cell lung cancer cells.
    Cancer Lett, 223(2): 249-58. [Abstract] [Full-text]
  93. The DNA repair gene ERCC2/XPD polymorphism Arg 156Arg (A22541C) and risk of lung cancer in a Chinese population.
    Cancer Lett, 223(2): 219-26. [Abstract] [Full-text]
  94. The regulation of feeding and metabolic rate and the prevention of murine cancer cachexia with a small-molecule melanocortin-4 receptor antagonist.
    Endocrinology, 146(6): 2766-73. [Abstract] [Full-text]
  95. Cooperation of amphiregulin and insulin-like growth factor-1 inhibits Bax- and Bad-mediated apoptosis via a protein kinase C-dependent pathway in non-small cell lung cancer cells.
    J Biol Chem, 280(20): 19757-67. [Abstract] [Full-text]
  96. XPC polymorphisms and lung cancer risk.
    Int J Cancer, 115(5): 807-13. [Abstract] [Full-text]
  97. Real-time RT-PCR detection of CK19, CK7 and MUC1 mRNA for diagnosis of lymph node micrometastases in non small cell lung carcinoma.
    Int J Cancer, 115(5): 777-82. [Abstract] [Full-text]
  98. Induction of cytotoxicity in human lung adenocarcinoma cells by 6-O-carboxypropyl-alpha-tocotrienol, a redox-silent derivative of alpha-tocotrienol.
    Int J Cancer, 115(5): 839-46. [Abstract] [Full-text]
  99. Restoration of Wnt-7a expression reverses non-small cell lung cancer cellular transformation through frizzled-9-mediated growth inhibition and promotion of cell differentiation.
    J Biol Chem, 280(20): 19625-34. [Abstract] [Full-text]
  100. Immune selection and emergence of aggressive tumor variants as negative consequences of Fas-mediated cytotoxicity and altered IFN-gamma-regulated gene expression.
    Cancer Res, 65(10): 4376-88. [Abstract] [Full-text]
  101. HER2 overexpression increases sensitivity to gefitinib, an epidermal growth factor receptor tyrosine kinase inhibitor, through inhibition of HER2/HER3 heterodimer formation in lung cancer cells.
    Cancer Res, 65(10): 4253-60. [Abstract] [Full-text]
  102. Inhibitors of the arachidonic acid pathway and peroxisome proliferator-activated receptor ligands have superadditive effects on lung cancer growth inhibition.
    Cancer Res, 65(10): 4181-90. [Abstract] [Full-text]
  103. Ki-67 immunoreactivity in the differential diagnosis of pulmonary neuroendocrine neoplasms in specimens with extensive crush artifact.
    Am J Clin Pathol, 123(6): 874-8. [Abstract] [Full-text]
  104. Fucosylation of serum glycoproteins in lung cancer patients.
    Clin Chem Lab Med, 43(4): 361-9. [Abstract] [Full-text]
  105. Chromosomal abnormalities in bronchial epithelium from smokers, nonsmokers, and lung cancer patients.
    Cancer Genet Cytogenet, 159(2): 137-42. [Abstract] [Full-text]
  106. Gefitinib treatment affects androgen levels in non-small-cell lung cancer patients.
    Br J Cancer, 92(10): 1877-80. [Abstract] [Full-text]
  107. A prospective longitudinal study of performance status, an inflammation-based score (GPS) and survival in patients with inoperable non-small-cell lung cancer.
    Br J Cancer, 92(10): 1834-6. [Abstract] [Full-text]
  108. Variability in organ-specific EGFR mutational spectra in tumour epithelium and stroma may be the biological basis for differential responses to tyrosine kinase inhibitors.
    Br J Cancer, 92(10): 1922-6. [Abstract] [Full-text]
  109. Establishment of a human non-small cell lung cancer cell line resistant to gefitinib.
    Int J Cancer, 116(1): 36-44. [Abstract] [Full-text]
  110. Increased plasma MMP9 in integrin alpha1-null mice enhances lung metastasis of colon carcinoma cells.
    Int J Cancer, 116(1): 52-61. [Abstract] [Full-text]
  111. Lung cancer risk: effect of dairy farming and the consequence of removing that occupational exposure.
    Am J Epidemiol, 161(11): 1037-46. [Abstract] [Full-text]
  112. Autocrine and paracrine regulation of interleukin-8 expression in lung cancer cells.
    Am J Respir Cell Mol Biol, 32(6): 540-7. [Abstract] [Full-text]
  113. Evaluation of tumour vascularisation in two rat sarcoma models for studying isolated lung perfusion. Injection route determines the origin of tumour vessels.
    Eur Surg Res, 37(2): 92-9. [Abstract] [Full-text]
  114. Charcoal cigarette filters and lung cancer risk in Aichi Prefecture, Japan.
    Cancer Sci, 96(5): 283-7. [Abstract] [Full-text]
  115. Genetic linkage between Pol iota deficiency and increased susceptibility to lung tumors in mice.
    Cancer Sci, 96(5): 256-9. [Abstract] [Full-text]
  116. Etoposide (VP-16) sensitizes p53-deficient human non-small cell lung cancer cells to caspase-7-mediated apoptosis.
    Apoptosis, 10(3): 643-50. [Abstract] [Full-text]
  117. Phase II study of irinotecan plus cisplatin induction followed by concurrent twice-daily thoracic irradiation with etoposide plus cisplatin chemotherapy for limited-disease small-cell lung cancer.
    J Clin Oncol, 23(15): 3488-94. [Abstract] [Full-text]
  118. Phase II trial of postoperative adjuvant paclitaxel/carboplatin and thoracic radiotherapy in resected stage II and IIIA non-small-cell lung cancer: promising long-term results of the Radiation Therapy Oncology Group--RTOG 9705.
    J Clin Oncol, 23(15): 3480-7. [Abstract] [Full-text]
  119. Peroxiredoxin-I is an autoimmunogenic tumor antigen in non-small cell lung cancer.
    FEBS Lett, 579(13): 2873-7. [Abstract] [Full-text]
  120. Expression and localization of mRNAs for matrix metalloproteinases and their inhibitors in mixed bronchioloalveolar carcinomas with invasive components.
    Mod Pathol, 18(6): 828-37. [Abstract] [Full-text]
  121. Pulmonary intestinal-type adenocarcinoma does not show enteric differentiation by immunohistochemical study.
    Mod Pathol, 18(6): 816-21. [Abstract] [Full-text]
  122. Malignancy-associated X chromosome allelic losses in foregut endocrine neoplasms: further evidence from lung tumors.
    Mod Pathol, 18(6): 795-805. [Abstract] [Full-text]
  123. CpG island methylation and expression of tumour-associated genes in lung carcinoma.
    Eur J Cancer, 41(8): 1223-36. [Abstract] [Full-text]
  124. Birth cohort effect on lung cancer incidence in Taiwanese women 1981-1998.
    Eur J Cancer, 41(8): 1170-7. [Abstract] [Full-text]
  125. Docetaxel administration schedule: from fever to tears? A review of randomised studies.
    Eur J Cancer, 41(8): 1117-26. [Abstract] [Full-text]
  126. A new murine tumor model for studying HLA-A2-restricted anti-tumor immunity.
    Cancer Lett, 224(1): 153-66. [Abstract] [Full-text]
  127. Gefitinib (ZD1839, Iressa) in non-small-cell lung cancer: a review of clinical trials from a daily practice perspective.
    Fundam Clin Pharmacol, 19(3): 385-93. [Abstract] [Full-text]
  128. Micropapillary pattern: a distinct pathological marker to subclassify tumours with a significantly poor prognosis within small peripheral lung adenocarcinoma (</=20 mm) with mixed bronchioloalveolar and invasive subtypes (Noguchi's type C tumours).
    Histopathology, 46(6): 677-84. [Abstract] [Full-text]
  129. Prognostic significance of p27Kip1, p45Skp2 and Ki67 expression profiles in Merkel cell carcinoma, extracutaneous small cell carcinoma, and cutaneous squamous cell carcinoma.
    Histopathology, 46(6): 614-21. [Abstract] [Full-text]
  130. Results of combined-modality therapy for limited-stage small cell lung carcinoma in the elderly.
    Cancer, 103(11): 2349-54. [Abstract] [Full-text]
  131. High incidence of disease recurrence in the brain and leptomeninges in patients with nonsmall cell lung carcinoma after response to gefitinib.
    Cancer, 103(11): 2344-8. [Abstract] [Full-text]
  132. Volumetric measurement of synthetic lung nodules with multi-detector row CT: effect of various image reconstruction parameters and segmentation thresholds on measurement accuracy.
    Radiology, 235(3): 850-6. [Abstract] [Full-text]
  133. Prognostic value of dynamic MR imaging for non-small-cell lung cancer patients after chemoradiotherapy.
    J Magn Reson Imaging, 21(6): 775-83. [Abstract] [Full-text]
  134. Irreversible inhibitors of the EGF receptor may circumvent acquired resistance to gefitinib.
    Proc Natl Acad Sci U S A, 102(21): 7665-70. [Abstract] [Full-text]
  135. Cerebral ischemic events in patients with advanced lung or prostate cancer.
    Neuroepidemiology, 24(4): 230-6. [Abstract] [Full-text]
  136. Detection of lung cancer by sensor array analyses of exhaled breath.
    Am J Respir Crit Care Med, 171(11): 1286-91. [Abstract] [Full-text]
  137. Thymidine phosphorylase expression in tumour cells and tumour response to capecitabine plus docetaxel chemotherapy in non-small cell lung cancer.
    J Clin Pathol, 58(6): 650-4. [Abstract] [Full-text]
  138. Cancer death epidemics in United States Black males: evaluating courses, causation, and cures.
    Prev Med, 41(2): 380-5. [Abstract] [Full-text]
  139. Immunopotentiation of NKT cells by low-protein diet and the suppressive effect on tumor metastasis.
    Cell Immunol, 231(1): 96-102. [Abstract] [Full-text]
  140. Analysis of treatment practices for elderly cancer patients in Ontario, Canada.
    J Clin Oncol, 23(16): 3802-10. [Abstract] [Full-text]
  141. Randomized phase III intergroup trial of etoposide and cisplatin with or without paclitaxel and granulocyte colony-stimulating factor in patients with extensive-stage small-cell lung cancer: Cancer and Leukemia Group B Trial 9732.
    J Clin Oncol, 23(16): 3752-9. [Abstract] [Full-text]
  142. Autofluorescence bronchoscopy with white light bronchoscopy compared with white light bronchoscopy alone for the detection of precancerous lesions: a European randomised controlled multicentre trial.
    Thorax, 60(6): 496-503. [Abstract] [Full-text]
  143. The spectrum of pulmonary mucinous cystic neoplasia : a clinicopathologic and immunohistochemical study of ten cases and review of literature.
    Am J Clin Pathol, 124(1): 62-70. [Abstract] [Full-text]
  144. Frequent inactivation of RASSF1A, BLU, and SEMA3B on 3p21.3 by promoter hypermethylation and allele loss in non-small cell lung cancer.
    Cancer Lett, 225(1): 131-9. [Abstract] [Full-text]
  145. Experimental model of pulmonary metastasis treatment with IFNalpha.
    Cancer Lett, 225(1): 75-83. [Abstract] [Full-text]
  146. Lung cancer: Preoperative pulmonary evaluation of the lung resection candidate.
    Am J Med, 118(6): 578-83. [Abstract] [Full-text]
  147. Phase III study of the Eastern Cooperative Oncology Group (ECOG 2597): induction chemotherapy followed by either standard thoracic radiotherapy or hyperfractionated accelerated radiotherapy for patients with unresectable stage IIIA and B non-small-cell lung cancer.
    J Clin Oncol, 23(16): 3760-7. [Abstract] [Full-text]
  148. CD13 (aminopeptidase N) can associate with tumor-associated antigen L6 and enhance the motility of human lung cancer cells.
    Int J Cancer, 116(2): 243-52. [Abstract] [Full-text]
  149. Overexpression of S100A2 protein as a prognostic marker for patients with stage I non small cell lung cancer.
    Int J Cancer, 116(2): 285-90. [Abstract] [Full-text]
  150. Video-thoracoscopy and staged management of preoperative empyema in lung cancer.
    Thorac Cardiovasc Surg, 53(3): 188-90. [Abstract] [Full-text]
  151. Pulmonary dirofilariasis mimicking lung tumor with chest wall and mediastinal invasion.
    Thorac Cardiovasc Surg, 53(3): 173-5. [Abstract] [Full-text]
  152. Carcinoid tumors of the lung and multimodal therapy.
    Thorac Cardiovasc Surg, 53(3): 168-72. [Abstract] [Full-text]
  153. Surgical treatment for lung cancer with COPD based on the Global Initiative for Chronic Obstructive Lung Disease (GOLD).
    Thorac Cardiovasc Surg, 53(3): 162-7. [Abstract] [Full-text]
  154. Space-time models with time-dependent covariates for the analysis of the temporal lag between socioeconomic factors and lung cancer mortality.
    Stat Med, 24(12): 1919-32. [Abstract] [Full-text]
Place a permanent text-link or advertisement here for just US$15.

© 2004-2008 Lung Cancer Research Today. All Rights Reserved.

Lung Cancer Research Today Archive:

Volume 1 (2004)
  Issue 1 (August)
  Issue 2 (September)
  Issue 3 (October)
  Issue 4 (November)
  Issue 5 (December)

Volume 2 (2005)
  Issue 1 (January)
  Issue 2 (February)
  Issue 3 (March)
  Issue 4 (April)
  Issue 5 (May)
  Issue 6 (June)
  Issue 7 (July)
  Issue 8 (August)
  Issue 9 (September)
  Issue 10 (October)
  Issue 11 (November)
  Issue 12 (December)

Volume 3 (2006)
  Issue 1 (January)
  Issue 2 (February)
  Issue 3 (March)
  Issue 4 (April)
  Issue 5 (May)
  Issue 6 (June)
  Issue 7 (July)
  Issue 8 (August)
  Issue 9 (September)
  Issue 10 (October)
  Issue 11 (November)
  Issue 12 (December)

Volume 4 (2007)
  Issue 1 (January)
  Issue 2 (February)
  Issue 3 (March)
  Issue 4 (April)
  Issue 5 (May)
  Issue 6 (June)
  Issue 7 (July)
  Issue 8 (August)
  Issue 9 (September)
  Issue 10 (October)
  Issue 11 (November)
  Issue 12 (December)

Volume 5 (2008)
  Issue 1 (January)
  Issue 2 (February)
  Issue 3 (March)
  Issue 4 (April)
  Issue 5 (May)



Lung Cancer Books

Surviving Lung Cancer: (My Story)

Surviving Lung Cancer: (My Story)